TScan Therapeutics to Launch Pivotal TSC-101 Trial in Q2 2026 Following Strong Phase 1 Data & FDA Agreement

summarizeSummary

TScan Therapeutics announced positive Phase 1 data for its lead candidate, TSC-101, in heme malignancies, leading to an agreement with the FDA on pivotal trial design and a planned launch in Q2 2026.

check_boxKey Events

• Pivotal Trial for TSC-101

  TScan Therapeutics plans to launch a pivotal study for its lead TCR-T cell therapy candidate, TSC-101, in Q2 2026, targeting residual disease in heme malignancies.

• Positive Phase 1 Data

  Updated ALLOHA™ Phase 1 data for TSC-101 showed favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52), with 100% (3/3) of 2-year post-HCT patients remaining relapse-free and no dose-limiting toxicities.

• FDA Agreement on Trial Design

  The company has reached an agreement with the FDA on the pivotal trial design for TSC-101, mirroring the Phase 1 study with relapse-free survival as the primary endpoint.

• Significant Commercial Opportunity

  TSC-101 is projected to generate over $1 billion annually at peak penetration in the U.S., addressing a clear unmet need in a concentrated market.

auto_awesomeAnalysis

This 8-K filing, accompanied by a corporate presentation, signals a significant advancement for TScan Therapeutics' lead candidate, TSC-101. The positive Phase 1 data, demonstrating favorable relapse-free survival and overall survival with good tolerability, substantially de-risks the program. The agreement with the FDA on the pivotal trial design provides a clear path forward for regulatory approval. For a company of this size, moving a lead asset into a pivotal study with such promising early data and a projected multi-billion dollar peak revenue opportunity is a major catalyst, indicating strong potential for future growth and value creation.